XJPX
7702
Market cap68mUSD
Oct 09, Last price
445.00JPY
1D
0.91%
1Q
-5.52%
Jan 2017
-26.57%
Name
JMS Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
JMS Co., Ltd., established in 1947 and headquartered in Hiroshima, Japan, specializes in the development, manufacture, distribution, and global trade of a wide array of medical devices and pharmaceuticals. Its extensive product catalog serves both Japanese and international markets, addressing diverse medical needs. The company provides a comprehensive range of items for infusion and transfusion therapy, including infusion/transfusion sets (some featuring needle-free access ports), single-use needles and syringes, secure scalp vein sets, safe intravenous catheters, extension tubing, oral and enteral feeding systems, infusion and syringe delivery pumps, devices for administering semi-solid nutritional supplements, as well as blood bags, blood collection scales and mixers, high-frequency tube sealing equipment, and serum collection apparatus. For general medical use, JMS offers essential consumables for healthcare institutions such as surgical and examination gloves (both latex and plastic), treatment drapes, surgical gowns, protective masks and caps, drainage receptacles, and surgical adhesive tapes. Furthermore, JMS is a key supplier for hemodialysis and peritoneal dialysis, providing centralized dialysate delivery systems, hemodialysis units, AV fistula needles, systems designed to prevent accidental needlestick injuries, blood tubing sets for hemodialysis, dialyzers, pre-filled syringes, complete hemodialysis kits, single-patient dialysis devices, dialysis solutions for Continuous Ambulatory Peritoneal Dialysis (CAPD), and automated peritoneal dialysis equipment. The company also offers specialized products for cardiovascular therapy, which encompass cardiopulmonary support systems, membrane oxygenators, heat exchange units, pacemakers, microcatheters, and blood tubing sets for cardiopulmonary bypass.
Key people
Hiroaki Okukubo
Chairman of the Board · since 2024
Yasuhiro Awane
Vice President, Chief Director of Sales, Director · since 2025
Toru Sakoda
Chief Director of Global Marketing, Director · since 2023
Yoshiki Ochiai
Executive Officer, Chief Director of Corporate, Director of Human Resources in Main Corporate Business Unit · since 2025
Eiji Banshoya
Executive Officer, Senior Director of Surgical and Sales Business Unit · since 2023
Kimihiko Ikeda
Executive Officer, Senior Director of Hospital Products Business Unit · since 2025
Hiroyuki Iwasaki
Executive Officer, Izumo Plant Manager in Main Production Unit · since 2024
Hideyuki Kadohiro
Executive Officer, Manager of Business Strategy Office · since 2025
Masahiko Kumasaki
Executive Officer, Chief Director of Pharmaceutical Affairs and Quality Assurance · since 2024
Masayuki Naito
Executive Officer, Director of China Business in Main Global Marketing Unit · since 2023
Mamoru Nakamura
Executive Officer, Miyoshi Plant Manager in Main Production Unit, Director of Production and Administration in Main Production Unit · since 2023
Shogo Yanagida
Chief Director of Production, Director · since 2025
Ryuji Katsura
President, Representative Director · since 2023
Yoshio Kondo
Director · since 2023
Raita Uematsu
Chief Director of Research and Development, Director · since 2023
Kazuo Ikemura
Independent Director · since 2015
Shozo Ishizaka
Independent Director · since 2019
Akira Mito
Independent Director · since 2023
Yoshiharu Sagami
Independent Director · since 2023
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||